Background: Sudden sensorineural hearing loss (SSNHL) typically affects one ear and is often linked to various underlying causes. However, bilateral SSNHL (BSSHL), where both ears are affected, is much rarer and presents a more severe clinical challenge.
Aims/objectives: To report the clinical features and short-term outcomes of patients with BSSHL.
Material And Methods: The clinical features and outcomes of cases with BSSHL treated in between January 2016 and November 2024 were retrospectively analyzed.
Results: A total of 1212 cases with SSNHL were collected, and only 24 cases showed BSSHL (2.0%). The average hearing thresholds before treatment in the simultaneous onset group were significantly higher than that of the sequential onset group ( < .05). After prednisolone therapy, the effective rate of cases treated within 7 days was 18.2%, significantly higher than that of cases (0%) treated after 7 days ( < .05).
Conclusions And Significance: BSSHL is more common in females and may be related to viral infection. Simultaneous BSSHL is more common than sequential BSSHL. Hearing loss in patients with simultaneous onset of BSSHL is more severe than those with sequential onset. Prednisolone treatment for BSSHL within 7 days is critical for recovery.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/00016489.2025.2451735 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Factors Associated With Semaglutide Initiation Among Adults With Obesity.
JAMA Netw Open
January 2025
Department of Global Health, School of Public Health, Boston University, Boston, Massachusetts.
Importance: Semaglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist medication, was approved for weight management in individuals with obesity in June 2021. There is limited evidence on factors associated with uptake among individuals in this subgroup without diabetes.
Objective: To explore factors associated with semaglutide initiation among a population of commercially insured individuals with obesity but no diagnosed diabetes.
Novel Meningoencephalomyelitis Associated With Vimentin IgG Autoantibodies.
JAMA Neurol
January 2025
Department of Neurology, Xuanwu Hospital Capital Medical University, National Center for Neurological Disorders, Beijing, China.
Importance: Autoantibodies targeting astrocytes, such as those against glial fibrillary acidic protein (GFAP) or aquaporin protein 4, are crucial diagnostic markers for autoimmune astrocytopathy among central nervous system (CNS) autoimmune disorders. However, diagnosis remains challenging for patients lacking specific autoantibodies.
Objective: To characterize a syndrome of unknown meningoencephalomyelitis associated with an astrocytic autoantibody.
Fundus Autofluorescence Variation in Geographic Atrophy of Age-Related Macular Degeneration: A Clinicopathologic Correlation.
Invest Ophthalmol Vis Sci
January 2025
Vitreous Retina Macula Consultants of New York, New York, United States.
Purpose: The purpose of this study was to develop ground-truth histology about contributors to variable fundus autofluorescence (FAF) signal and thus inform patient selection for treating geographic atrophy (GA) in age-related macular degeneration (AMD).
Methods: One woman with bilateral multifocal GA, foveal sparing, and thick choroids underwent 535 to 580 nm excitation FAF in 6 clinic visits (11 to 6 years before death). The left eye was preserved 5 hours after death.
Machine learning-based prognostic model for patients with anaplastic thyroid carcinoma.
Discov Oncol
January 2025
Department of Thyroid Breast Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
Objective: Despite the identification of various prognostic factors for anaplastic thyroid carcinoma (ATC) patients over the years, a precise prognostic tool for these patients is still lacking. This study aimed to develop and validate a prognostic model for predicting survival outcomes for ATC patients using random survival forests (RSF), a machine learning algorithm.
Methods: A total of 1222 ATC patients were extracted from the Surveillance, Epidemiology, and End Results (SEER) database and randomly divided into a training set of 855 patients and a validation set of 367 patients.
Recent advances in therapeutic strategies of Erdheim-Chester disease.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Pharmaceutical Technology, Shree S K Patel College of Pharmaceutical Education and Research, Ganpat University, 384012, Mahesana, Gujarat, India.
Erdheim-Chester disease (ECD) is a rare form of non-LCH characterized by excessive accumulation of histiocytes in various tissues, leading to significant morbidity. The estimated prevalence of ECD is low, with fewer than 1000 cases reported globally, yet it presents considerable clinical challenges due to its heterogeneous manifestations, which include bone pain, cardiovascular complications, and neurological symptoms. Traditional treatment approaches, primarily involving corticosteroids and chemotherapy, have limitations, including inconsistent responses and significant side effects.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!